NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Biotech Hunter

Timeline

Start Date

September 30, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

September 30, 2026

Conditions

Advanced Breast CancerMetastatic Breast CancerBreast CancerBreast CarcinomaCancer of the BreastCancer of BreastMalignant Tumor of BreastBreast Tumor

Interventions

DRUG

NUV-422

NUV-422 is an investigational drug for oral dosing.

DRUG

Fulvestrant

Trial Locations (5)

Pennsylvania Cancer Specialists and Research Institute, Gettysburg

NEXT Virginia, Fairfax

Gabrail Cancer Center Research, Canton

Compassionate Cancer Care Research Inc., Fountain Valley

Pacific Cancer Medical Center, Inc., Anaheim